Component supply stabilises, but dual sourcing remains the norm

Lead times for several critical device components have returned to near pre-disruption levels. Pressure sensors, peristaltic pumps, and medical-grade tubing are now quoted in weeks rather than quarters, and some suppliers have resumed normal allocation policies after several years of constraint. Prices, however, have not returned to earlier levels, and several manufacturers report that renegotiation attempts have met with very little movement.

Manufacturers are not unwinding the changes made during the shortage. Dual sourcing, previously reserved for high-volume lines, is now common even on lower-volume platforms, despite the validation cost. Qualifying a second supplier for a sterile component typically requires revalidation of the affected process, which can take six months and consumes engineering capacity that would otherwise be spent on new product development.

The cost of that insurance is visible in gross margins, particularly for smaller firms that cannot spread validation work across many product families. Several have responded by standardising on a smaller number of component platforms so that one qualification covers more finished devices, which reduces variety in the catalogue but makes the supply base considerably easier to manage and audit.

Procurement managers describe a lasting change in behaviour: supplier risk is now reviewed at the design stage rather than at purchase. Specifying a single-source custom part is increasingly questioned in design reviews, and some quality systems now require a documented justification for doing so. The practical effect is that design cycles are slightly longer, but the number of emergency supplier changes after launch has fallen.